Skip to Main Content

Paper Details

Effect of Personalized Breast Cancer Risk Tool on Chemoprevention and Breast Imaging: ENGAGED-2 Trial.
JNCI Cancer Spectr
5
2021
Breast Cancer, Women, breast cancer, cancer, patient, raloxifene, tamoxifen, women
Author NameAffiliation
Karen J WernliKaiser Permanente Washington Health Research Institute
Karen J WernliKaiser Permanente Washington Health Research Institute
Kathleen A LeppigWashington Permanente Medical Group
Stephen M SchwartzLombardi Comprehensive Cancer Center, Georgetown University Medical Center
  • 1 - 4

Datasets

Release 1.2